The report covers 40+ companies and 50+ pipeline drugs. Explore drug profiles from clinical to nonclinical stages, assessment by product type, and detailed pipeline development activities. Key players ...

The market expects Agios Pharmaceuticals (AGIO) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus ...

BofA lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $52 from $54 and keeps a Buy rating on the shares. While Q1 earnings ...

In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Agios Pharma (AGIO – Research Report), ...

HERZLIYA, Israel and CALGARY, AB, April 15, 2025 /PRNewswire/ -- Innocan Pharma Corporation (the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed its ...

BERLIN--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME ...

During the National Republican Congressional Committee dinner in Washington, D.C., President Trump said that his administration would "very shortly" announce tariffs on pharmaceuticals. April 9, 2025 ...

HERZLIYA, Israel and CALGARY, AB, April 7, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in ...